Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cell and Cancer Research

Executive Summary. Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of ROCK1 and ROCK2, displaying an IC₅₀ of ~140 nM for ROCK1 and >200-fold selectivity against unrelated kinases (APExBIO, product page). It disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and impairs cytokinesis in diverse cell types (Pereira et al. 2024). Y-27632 enhances human stem cell viability and suppresses tumor invasion/metastasis in mouse models. Its selectivity and reproducible activity have made it a standard for probing Rho/ROCK signaling in vitro and in vivo (internal article). Correct handling—such as solubilization, temperature control, and stock management—is essential to preserve activity and avoid experimental artifacts.

Biological Rationale

Rho-associated protein kinases (ROCK1, ROCK2) are serine/threonine kinases central to cytoskeletal dynamics, cell motility, and proliferation. ROCK kinases translate Rho GTPase activation into actin-myosin contractility, stress fiber formation, and focal adhesion assembly. Dysregulation of Rho/ROCK signaling is implicated in cancer progression, fibrosis, and neurodevelopmental disorders (Pereira et al. 2024). Effective chemical inhibition of ROCK1/2 is critical for dissecting the role of this pathway in cellular morphogenesis, stem cell maintenance, and tumor invasion. Y-27632 dihydrochloride, supplied by APExBIO (SKU: A3008), is widely regarded as the reference small-molecule ROCK inhibitor due to its potency and target selectivity (A3008 kit).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds selectively to the ATP-binding site within the catalytic domains of ROCK1 and ROCK2. This interaction competitively inhibits kinase activity, blocking downstream phosphorylation of substrates such as myosin light chain (MLC) and LIM kinase. The compound's IC₅₀ is ~140 nM for ROCK1, with a K_i of 300 nM for ROCK2 (APExBIO). Selectivity exceeds 200-fold over other kinases including PKC, MLCK, cAMP-dependent protein kinase, and PAK.

Downstream effects include inhibition of Rho-mediated actin cytoskeleton reorganization, suppression of stress fiber assembly, decreased cell contractility, and altered cell cycle progression from G1 to S phase. Y-27632 also blocks cytokinesis, leading to an accumulation of multinucleated cells in sensitive cell types. These phenotypes are directly attributable to ROCK pathway inhibition and have been validated in primary cells, cell lines, and in vivo models (Pereira et al. 2024).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM under in vitro kinase assay conditions (APExBIO, product page).
• Demonstrates >200-fold selectivity versus PKC, PKA, MLCK, and PAK in comparative kinase profiling (Pereira et al. 2024).
• Suppresses proliferation of human prostatic smooth muscle cells in a concentration-dependent manner (10–100 μM, 37°C, 5% CO₂) (internal article).
• Enhances viability of human pluripotent stem cells when added at 10 μM during passaging or cryorecovery (see also internal use-case).
• Inhibits tumor invasion and metastasis in mouse xenograft models by interfering with Rho/ROCK-mediated cytoskeletal remodeling (Pereira et al. 2024).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C; warming to 37°C or sonication further enhances dissolution (APExBIO, spec sheet).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used across a spectrum of research contexts:

• Stem Cell Research: Promotes survival and expansion of human embryonic and induced pluripotent stem cells during passaging (internal reference).
• Cancer Biology: Reduces tumor cell invasion, migration, and metastasis in both in vitro and animal models.
• Cytoskeletal Studies: Disrupts Rho-mediated stress fiber formation and focal adhesion dynamics.
• Cell Proliferation Assays: Modulates cell cycle progression and allows dissection of cytokinesis mechanisms.

Compared to earlier reviews that focus on strategic guidance, this article delivers atomic, quantitative benchmarks and clarifies selectivity profiles under defined conditions.

Common Pitfalls or Misconceptions

• Non-specific inhibition: At concentrations >100 μM, off-target effects on other kinases may occur. Stick to validated ranges (1–50 μM) for specificity (Pereira et al. 2024).
• Solubility artifacts: Incomplete dissolution leads to precipitation and unreliable dosing. Use DMSO or pre-warmed water and verify clarity before use (APExBIO).
• Long-term solution storage: Extended storage (>2 months) of working solutions at -20°C may reduce potency. Prepare fresh stocks when possible.
• Misattribution of effects: Not all cytoskeletal or proliferation changes are ROCK-dependent. Confirm with orthogonal inhibitors or genetic controls.
• In vivo translation: Dose and pharmacokinetics in animal models may not match in vitro potencies; titrate and validate accordingly.

Workflow Integration & Parameters

For routine use, dissolve Y-27632 dihydrochloride (APExBIO A3008) at 10–20 mM in DMSO, aliquot, and store at -20°C, desiccated. Working concentrations typically range from 1 to 50 μM depending on cell type and endpoint. Avoid repeated freeze-thaw cycles. For aqueous preparations, pre-warm to 37°C or use ultrasonic bath to enhance solubility. Always verify solution clarity before adding to media.

For stem cell applications, add 10 μM Y-27632 immediately after passaging or thawing. In cancer cell migration assays, pre-treat cells 30 min prior to migration/invasion stimuli. For in vivo studies, consult existing pharmacokinetic data and titrate dose accordingly. See product page for detailed protocols.

This article extends prior workflow-focused guides (see here) by providing peer-reviewed benchmarks and clarifying preparation/handling caveats.

Conclusion & Outlook

Y-27632 dihydrochloride is a benchmark, selective ROCK1/2 inhibitor with robust, reproducible effects on cytoskeletal organization, cell proliferation, and tumor biology. Its high selectivity and solubility profile enable precise modulation of the Rho/ROCK pathway in diverse models. As new in vitro systems and organoid models emerge, Y-27632 will remain essential for dissecting cytoskeletal and cell fate mechanisms. For further details, refer to the APExBIO A3008 product page and recent preclinical studies (Pereira et al. 2024).